St. John's Wort: Europe's Most-Studied Herbal Antidepressant

← Back to articles

In Germany, St. John’s Wort (Hypericum perforatum) is widely prescribed for mild-to-moderate depression. That is not folk practice — it is guideline-driven medicine built on more than 35 randomized trials and large Cochrane reviews. The most recent Cochrane meta-analysis (Linde et al., Cochrane Database of Systematic Reviews, 2008; PMID 18843608; 29 trials, 5,489 patients) concluded that standardized Hypericum extracts are superior to placebo and as effective as standard antidepressants for major depression, with fewer adverse events than older tricyclics or SSRIs. A more recent meta-analysis comparing St. John’s Wort with SSRIs specifically (Ng et al., Journal of Affective Disorders, 2017; PMID 28064110; 27 trials, 3,808 patients) reported comparable response and remission rates and significantly fewer dropouts due to adverse events.

The Active Compounds

The therapeutic effect is attributed to hyperforin and, to a smaller degree, hypericin. Hyperforin inhibits reuptake of serotonin, norepinephrine, dopamine, GABA, and glutamate at roughly comparable potency — an unusually broad neurochemical profile. Clinically studied extracts are standardized to either 3–6% hyperforin (such as WS 5570 and LI 160) or 0.3% hypericin, with the hyperforin-standardized extracts having the stronger evidence base for depression. Extracts without standardization or with hyperforin below 3% have produced the null results that surface in some U.S.-based trials.

Dosing That Works

Effective clinical doses are 600–1,800 mg/day of standardized extract, most commonly 300 mg three times daily. Onset is 2–4 weeks, similar to SSRIs. For severe depression, St. John’s Wort is not a substitute. The Hypericum Depression Trial Study Group (JAMA, 2002; PMID 11926934) randomized 340 outpatients with major depression of at least moderate severity to St. John’s Wort, sertraline, or placebo for 8 weeks; neither active arm separated from placebo on the primary outcomes. The lesson is that severity of presentation strongly moderates response — both for SSRIs and for the herb.

The Drug Interaction Problem (High-Stakes)

Hyperforin is a potent inducer of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein, which together metabolize and transport roughly 50% of prescription drugs. Borrelli & Izzo (AAPS Journal, 2009; PMID 19859815) catalog the clinically significant interactions: oral contraceptive failure (breakthrough bleeding and unintended pregnancies have been reported), reduced cyclosporine and tacrolimus levels (with documented transplant rejections), reduced antiretroviral exposure (indinavir, nevirapine), reduced anticancer exposure (irinotecan, imatinib), reduced warfarin effect (raising thrombosis risk), and serotonin syndrome when combined with SSRIs or SNRIs. The herb should never be combined with MAOIs and requires a 2-week washout before starting any new antidepressant. Photosensitivity is the most common direct side effect at high doses. The U.S. FDA, the European Medicines Agency, and Health Canada all advise patients to disclose St. John’s Wort use to any clinician prescribing other medication.

Where It Fits

St. John’s Wort is best positioned as a first-line option for mild-to-moderate depression in patients who (a) are not on interacting medications, (b) have not responded to or tolerated SSRIs, or (c) prefer a botanical with a robust evidence base. It is not appropriate for bipolar depression (can trigger mania), severe or psychotic depression, or pregnancy. Use a hyperforin-standardized extract from a reputable manufacturer; the unstandardized products on U.S. shelves are often the source of negative trial results.